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ABSTRACT 
Kenetta L. Nunn: Influence of vaginal lactobacilli on barrier properties of cervicovaginal mucus against 
HIV 
(Under the direction of Samuel Lai) 
 
The vaginal epithelium is coated with cervicovaginal mucus (CVM), a dense mesh network of 
mucin fibers that HIV in semen must penetrate in order to reach target cells residing in the epithelium.  
Trapping HIV in CVM offers the potential to prevent initial HIV infections altogether, and likely 
accounts in part for the generally low rates of HIV transmission (~1 in 100-1000 coital acts).  CVM is 
populated by a dense microbial community that can differ markedly between women as well as in the 
same woman over time, and epidemiological studies indicate that the microbiota can significantly impact 
the risk of acquiring HIV.  Nevertheless, little is understood about whether specific microbes, including 
different species of Lactobacillus, may modulate the barrier properties of CVM against HIV.  In this 
thesis, I decided to investigate whether differences in the vaginal microbiota may result in differential 
ability of native CVM to immobilize and trap HIV.  Using high-resolution particle tracking, I found that 
HIV mobility across different CVM specimens was not correlated to vaginal pH or total lactic acid levels, 
and only slightly correlated to Nugent scores.  Instead, I found that HIV readily penetrates CVM with low 
levels of D-lactic acid (D-LA), but is consistently trapped in CVM with high D-LA levels.  Based on 
vaginal microbiome analysis using high throughput 16S rRNA gene sequencing, I confirmed that CVM 
specimens with low levels of native D-LA are more likely to possess a L.iners dominated microbiota, 
whereas CVM specimens with high levels of native D-LA are more likely to possess a L. crispatus 
dominated microbiota.  These results indicate that vaginal Lactobacilli spp. can alter the barrier properties 
of CVM against HIV, and that L. iners, rather than solely BV-associated microbes, may be correlated to 
increased susceptibility to HIV transmission relative to L. crispatus.     
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CHAPTER 1 
INTRODUCTION 
	  
1.1 Mucus as a Barrier 
Goblet cells secrete long glycoproteins called mucins, which happen to be the most abundant 
biopolymer in the body.  Mucin fibers entangle and crosslink forming a dense mucin matrix with shear-
dependent viscoelastic (i.e. mechanical) properties.  This dense mucin matrix forms the viscous and 
elastic gel of mucus, which coats the surfaces of the respiratory, gastrointestinal, and urogenital tracts. 
This mucus gel serves as the first line of defense against pathogens and infections at mucosal surfaces by 
acting as a selectively permeable barrier allowing entry of nutrients while blocking the entry of foreign 
and dangerous substances, including viral and bacterial pathogens [1]; and, as mucus is continuously 
cleared and renewed, particles trapped in the mucus layer are readily eliminated from the mucosal 
surface.  Furthermore, many protective factors such as defensins and antibodies are constantly secreted 
into mucus and can enhance its barrier properties [1].  This barrier function of mucus enables the body to 
breathe, ingest, and reproduce without succumbing to infections. 
Mucus coating the female reproductive tract, is predominantly derived from mucin-secreting 
glands in the cervix [2, 3].  Cervical mucus flows into the vagina by gravitational and/or abdominal 
pressure [4, 5], becomes exposed to a myriad of microbes (commensals or pathogenic) in the vagina (see 
more in Section 1.3), and undergoes a series of biochemical alterations that remain poorly understood to 
date [6, 7].  We refer to the secretions overlaying the vaginal epithelium as cervicovaginal mucus (CVM) 
to emphasize both its origin and the alterations by the vaginal microbiota.   
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The viscoelastic property of CVM enables it to behave like a gel excluding most infectious 
virions in semen from directly contacting the vaginal epithelium.  Although CVM can behave as a gel in 
this instance, it can readily shear thin and function as a lubricant when large and rapid shear forces are 
introduced, thereby preventing physical trauma during sexual intercourse [1, 3].  Furthermore, to ensure 
proper function, the composition of mucus is constantly changing.  For example, the properties of CVM 
are markedly altered by the menstrual cycle.  During non-ovulatory periods, the viscosity of CVM 
prevents sperm from reaching the upper reproductive tract. However, CVM becomes less viscous during 
ovulation enabling sperm to penetrate the mucus layer and swim through [1].  
	  
1.2 Innate and Adaptive Barrier Properties of Mucus  
Since viruses and other intracellular obligate bacteria must reach target cells to initiate infections, 
the ability of these pathogens to efficiently traverse mucus overlaying the vaginal epithelium represents 
the first step in the male to female transmission of sexually transmitted infections (STIs).  Conversely, the 
ability to trap pathogens in mucus, and consequently reduce the flux of pathogens arriving to target cells, 
offer the potential to reduce infections or prevent infections from taking place altogether. 
Native mucus can act directly as a diffusional barrier against pathogens, based on either steric 
obstruction by the dense matrix of mucin fibers, and/or by adhesive interactions between the pathogens 
and mucins, or other mucus constituents.  The microstructure of CVM was previously estimated to 
possess a mesh spacing of ~340 ± 70 nm, which suggests that CVM would pose significant steric 
obstruction to entities much larger than the mesh spacing, but not to viruses or pathogens that have other 
motility apparatus (e.g. beating flagella) [8].  It is likely then that the dominant mechanism of trapping 
pathogens in CVM involves adhesive interactions with the mucin mesh or other mucus constituents.  For 
example, native acidic CVM was previously shown to effectively immobilize HIV virions and likewise 
synthetic, virus-sized nanoparticles [9, 10].  
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Mucus may also work in conjunction with the adaptive immune system, namely via secreted 
antibodies, to block the translocation of pathogens.  Indeed, there are more antibodies secreted into the 
mucosa than the blood or lymph.  Antibodies can be delivered into mucus by the MHC class I-related 
neonatal Fc receptor [11]; this was suggested to account for ten-fold higher concentrations of IgG than 
IgA observed in CVM [12].  Alternatively, secreted antibodies may be produced in the local tissue and 
secreted into the lumen by resident plasma cells in a process regulated by M cells, which function as 
sensory checkpoints for the cellular immune system, and leads to B cell expansion and secretion of 
antigen-specific antibodies [1].   
Generally, antibodies can induce effector functions such as opsonization and antibody-dependent 
cell-mediated cytotoxicity (ADCC), and can also neutralize pathogens by blocking receptor-binding sites. 
Unfortunately, due to the low abundance of live immune cells and little compliment activity, these 
effector functions are limited in CVM from a healthy vagina.  Polymeric antibodies, such as sIgA and 
IgM, may also agglutinate pathogens into complexes that are too large to diffuse across mucus [1], but 
this mechanism is not likely to be a dominant mechanism of vaginal mucosal immunity given the far 
reduced quantities of sIgA generally found in CVM.  Alternatively, the Lai Lab has recently shown that 
mucosal IgG can interact with mucins to trap individual pathogens in mucus.  IgG diffuses rapidly 
through cervical mucus, slowed only slightly by transient adhesive interactions with mucins.  This almost 
unhindered diffusion allows IgG to accumulate rapidly on pathogen surfaces, and the resulting IgG array 
forms multiple weak adhesive crosslinks to mucus gel that effectively trap (immobilize) pathogens, 
preventing them from initiating infections.   Mucosal immunity based on IgG-mucin crosslinking was 
illustrated with herpes simplex virus serotype 1 (HSV-1), which readily penetrated fresh, pH-neutralized 
ex vivo samples of CVM with low or no detectable levels of anti-HSV-1 IgG, but was trapped in samples 
with even modest levels of anti-HSV-1 IgG [13].  The addition of exogenous anti-HSV-1 IgG, affinity-
purified from intravenous immunoglobulin, into samples with little or no endogenous anti-HSV-1 IgG 
trapped virions at concentrations below those needed for neutralization and with similar potency as 
endogenous IgG.  A non-neutralizing IgG against HSV-gG significantly protected mice against vaginal 
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infection, while removing vaginal mucus by gentle lavage abolished protection.  These observations 
suggest IgG-Fc possess a glycan-dependent “muco-trapping” effector function that may provide 
exceptionally potent protection at mucosal surfaces. 
 
1.3 The Vaginal Microbiota 
In a study using 16S rRNA gene profiling of the vaginal microbiome of nearly 400 non-pregnant 
women, five consistent groupings of the microbiota, termed community state types (CST), were identified 
[14].  Four of the CSTs were most often dominated by Lactobacillus sp. (CST-I: L. crispatus, CST-II: L. 
gasseri, CST-III: L. iners, and CST-V: L. jensenii) and represented approximately 73% of the samples, in 
good agreement with the prevailing view that Lactobacillus spp. are important members of vaginal 
microbiota (Figure 1.1).  L. iners was the most prevalent species, followed by L. crispatus.   Importantly, 
ethnicity was associated with CST (Figure 1.2). African-American and Hispanic women were more likely 
to be categorized as CST-III (L. iners dominant) or CST-IV (low Lactobacillus spp. and/or high 
anaerobes, including many BV-associated organisms such as G. vaginalis, Mobiluncus, and A. vaginae); 
these ethnic groups have been associated with greater risks of acquiring HIV [15-17].  This suggests that 
the composition and stability of the vaginal microbiota may serve as the physiological pathway relating 
ethnicity to HIV infection.  
A hallmark of Lactobacillus spp. is the continuous secretion of lactic acid (LA), which creates an 
acidic environment in CVM ranging from pH 3.5 to pH 4 under anaerobic conditions [18, 19].  L. iners, 
as well as L. gasseri and L. jensenii, are more frequently associated with moderately elevated pH (> 4.6) 
and higher Nugent scores (≥ 4) than L. crispatus (Figure 1.1).  Even in the presence of semen, the rapid 
secretion of lactic acid likely maintains an acidic environment where Lactobacillus is most abundant (i.e. 
near the epithelium), and the entire vagina becomes acidic again within minutes to hours (depending on 
rate of post-coital discharge of semen).  Lactobacillus spp., unlike the vaginal epithelium that can produce 
only the L-isomer of lactic acid, can secrete both D- and L- lactic acid although not all do [20].  Lactic 
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acid can produce a low pH environment that precludes vaginal colonization by nonindigenous organisms 
[18, 20-24], and recent evidence suggests lactic acid possesses increased antimicrobial activity beyond 
acidity alone [9, 18, 25, 26].  Lactic acid at low pH (<4.5) is a potent bactericide against BV-associated 
bacteria [18].  This may help explain why L. iners, which secrete more L-LA than D-LA [42], can more 
readily fend off BV-associated microbes and thus frequently observed in women with recurring episodes 
of BV. The recent finding by Tachedjian et al. that LA can inactivate HIV further highlight the potential 
dual roles of LA in enhancing the mucosal defense, by serving as a surrogate marker for a ‘protective’ 
microbiota, and also directly participating in the inactivation of HIV [25]. 
Lactic acid may also act as a signaling molecule influencing host gene expression and stimulating 
the host innate defense system by enhancing cytokine release in response to antigen exposure.  For 
example, L-lactic acid can stimulate the IL-23/IL-17 T lymphocyte pathway [27, 28], induce the 
production of pro-inflammatory cytokines by vaginal epithelial cells in the presence of a synthetic viral 
RNA [29] and activate lymphocytes [30].  Given that IL-23 is one of the primary cytokines involved in 
neutrophil recruitment, mobilization, and activation at mucosal surfaces, this may translate to better 
immune surveillance of mucosal surfaces with high lactic acid levels in vivo [28]. The LA-induced 
cytokine release is consistent with the findings of Fichorova et al. that colonization of vaginal epithelial 
cell monolayers with common bacteria such as L. crispatus may regulate the epithelial innate immunity 
[31].  
 
1.4 The Link between Vaginal Microbiota and Susceptibility to Sexually Transmitted Infections 
Various factors including a person’s diet and age, commensals, and pathogens can lead to 
changes in the physical properties of mucus.  Some of these changes involve an improper balance in 
viscoelasticity, which can lead to different disease conditions. One such disease state is bacterial 
vaginosis (BV).  In episodes of BV, an overgrowth of anaerobes often associated with BV causes the 
	  
	  
6	  
population of commensal lactobacilli to decrease. BV associated bacteria compromise the mucus barrier 
by secreting sialidase and other mucin degrading enzymes that reduce the viscoelasticity of mucus [1, 3]. 
Degradation of the mucus gel by this alteration in the vaginal microflora reduces the likelihood of mucins 
being able to effectively trap pathogens, and therefore, leads to increased risk for acquiring various STDs 
in patients that have BV.   
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Figure 1.1: Heatmap of relative abundance of micobial taxa found in the vaginal bacterial communities of 
reproductive age women.  Reproduced from [14]. 
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Figure 1.2: The distribution of community state types within each ethnic group of reproductive age 
women from the study in Figure 1.1.  Reproduced from [14]. 
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The following chapter (Chapter 2) is a manuscript that is currently in preparation for publication 
and I am the first author on the paper. I was involved in experimental design, data analysis/discussion, 
and writing of the manuscript. Also, I carried out the follow experimental procedures for the paper: 
recruitment of donors and collection of cervicovaginal mucus specimens, measurement of native pH as 
well as D- and L- lactic acid levels in CVM, Nugent scoring of CVM specimens, and multiple particle 
tracking of mCherry-labeled HIV-1 in CVM.   
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CHAPTER 2 
VAGINAL L. CRISPATUS BUT NOT L. INERS REINFORCES THE INNATE 
CERVICOVAGINAL MUCUS BARRIER AGAINST HIV 
 
2.1 INTRODUCTION 
Semen from HIV-infected individuals contains cell-free and cell-associated HIV. Both forms of 
virions are plausible mediators of male-to-female transmission of HIV in the female reproductive tract, 
and to be infectious both must penetrate the genital mucus secretions that coats and adheres to vaginal and 
penile epithelia during coitus.  While leukocytes can migrate through pH neutral mucus, they are rapidly 
immobilized and then killed by mild acidity (pH < 6), and hence are unlikely to survive in the acidic 
vagina.  In contrast, cell-free HIV is only slowly inactivated by mild acidity, and earlier work suggests 
that native, acidic CVM from women with presumably Lactobacilli-dominated microbiota were able to 
effectively immobilize HIV [9].  The adhesive interactions between HIV and mucins were only evident at 
native pH, as virions were not slowed substantially when the pH of CVM was neutralized. 
Interestingly, a later study following up on the aforementioned work suggested that CVM trapped 
HIV virions to a much lesser extent [32].  While that study did not describe the study participants and the 
method of recruitment, the variability in the native pH of the mucus specimens, including a large fraction 
of specimens with pH > 4, suggest the study involved a large number of subject who did not possess 
Lactobacilli-dominated microflora.  This, in turn, would be consistent with our observation that trapping 
of HIV in CVM is critically dependent on the native pH of the CVM specimens.  Nevertheless, the lack of 
vaginal Lactobacilli alone could not account for some of the CVM specimens with Nugent scores < 3 and 
pH < 4.5 that failed to trap or markedly slow HIV.
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I was thus interested in better understanding the factors that control HIV interactions with the mucosal 
environment and modulate the native barrier properties of CVM. 
 
2.2 RESULTS AND DISCUSSION 
To directly determine distinct mobility of HIV in different CVM specimens, I studied the motion 
of HIV virus-like particles (VLP) that were internally fluorescently labeled through the incorporation of a 
mCherry-Gag fusion capsid. For biosafety considerations, the derivative was replication defective and 
pseudotyped with a YU2, R5-tropic HIV envelope. I mixed the labeled HIV at minimal dilution (~5% 
[vol/vol]) into fresh, native and undiluted CVM, and observed the translational movements of hundreds of 
individual HIV virions in each sample using high-resolution multiple-particle tracking. 
To reconcile the varying observations of HIV mobility in genital secretions, I screened a larger 
subject pool than was included in our previous publication, and observed significant variation in the 
mobility of HIV VLPs that can be broadly divided into 2 categories: virions that are extensively trapped 
in CVM (n=13 out of 20), or virions that can readily penetrate CVM (n=7 out of 20).  In all CVM 
specimens, I also quantified the mobility of HIV-sized beads that were engineered with relatively muco-
inert surfaces, and carboxylated beads that may associate with mucins via hydrophobic interactions or 
hydrogen bonding.  In all CVM specimens, muco-inert beads exhibit rapid diffusion (Figure 2.1, 2.2), 
which indicates that HIV virions were becoming trapped in CVM specimens by adhesive interactions 
with the mucins or mucus constituents.  Mucoadhesive beads were also slowed significantly in CVM 
samples that failed to trap HIV, suggesting that the rapid mobility observed for HIV is due to a lack of 
adhesive interactions between the virions and the mucin mesh, rather than a compromised mucus gel 
(Figure 2.1, 2.2).  The mobility of HIV exhibits a slight but non-significant correlation to vaginal pH 
(Figure 2.3, 2.4).  While the average Nugent scores among samples that failed to trap HIV were higher, 
the difference was not significant, and over half the samples that exhibited low Nugent scores (0-3) failed 
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to trap HIV (Figure 2.3, 2.4).  Therefore, I sought to identify other biomarkers that may more accurately 
predict the barrier properties of CVM. 
I noted that only lactic acid producing bacteria can secrete both D- and L- LA (humans can only 
secrete L-LA, and do not contribute significantly to the total LA found in the vagina), and different 
species of Lactobacillus may differ in D- vs. L- LA secretion.  Therefore, I tested whether D- or L- LA 
levels in CVM could be a useful biomarker for evaluating the barrier properties of CVM.  I found D-LA 
was a substantially better predictor of Nugent scores than L-LA, pH of CVM or total LA levels (data not 
shown).  More importantly, I found that CVM samples that did not trap HIV possessed significantly 
lower D-LA levels (Figure 2.3, 2.4) but otherwise little to no difference in L-LA (Figure 2.3, 2.4) and 
total LA levels (Figure 2.3, 2.4).  Exogenous addition of D-LA to specimens with low D-LA did not 
facilitate HIV trapping (data not shown).  Interestingly, D-LA secretion by Lactobacillus in women with 
recurrent BV is also ~50% that of women with healthy vaginal microbiota: even in women experiencing 
recurring episodes of bacterial vaginosis (BV) with vaginal pH ≥ 5, up to 40% can carry one or more 
species/strains of Lactobacillus (most typically L. iners).  Their ability to make D-lactic acid is, however, 
low (3.94 ± 0.72 mM/L) compared to the D-lactic acid produced by Lactobacillus strains from healthy 
vagina with vaginal pH ∼4 (8.04 ± 1.07 mM/L) (P<0.001) [33].  Taken together, these results suggest D-
LA represents a sensitive biomarker of the vaginal microbiota that in turn modulates the barrier properties 
of CVM against infections. 
It should be pointed out that L. iners was frequently associated with transitions to other CST 
groups, especially CST-IV (BV-associated microbes).  Thus, L. iners likely represents a less stable 
microbial community than the other Lactobacillus-dominant groupings.  Unpublished work from Jacques 
Ravel’s lab in University of Maryland, based on metatranscriptomics analysis (catalogue and different 
expression of all expressed genes in a microbial community using sequence-based RNAseq approach), 
suggested that there is differential expression of L- and D- lactate dehydrogenase (LDH) between L. 
crispatus and L. iners, which led me to hypothesize that L. iners, rather than lactic acid, may be directly 
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responsible for the distinct barrier properties of CVM observed.  To confirm that the CVM samples that 
possessed both low D-LA and a low Nugent score are actually CVM from women with L. iners-
dominated microflora, we collaborated with Dr. Ravel’s lab at The University of Maryland to perform a 
broad 16S rRNA gene-based characterization of the vaginal microbial population of six additional CVM 
samples via high-throughput sequencing of the 16S rRNA gene V3-V4 regions on the Illumina MiSeq 
platform (250 bp paired end reads).  I found that 3 CVM samples that effectively trapped HIV all 
possessed a L. crispatus dominant microflora, whereas the 2 CVM samples that did not trap HIV both 
possessed largely L. iners- dominant microflora, and the remaining sample that could not trap HIV 
exhibited high amounts of G. vaginalis (Figure 2.5).   
Traditionally, the primary means of evaluating vaginal mucosal health, in regards to BV, have 
been by Amsel’s criteria and by Nugent scoring: a Lactobacillus-dominated microbiota, as reflected by 
Nugent scores in the 0-3 range and a pH < 4.5, was typically regarded as “healthy”.  Although this 
approach is useful in rapidly identifying women with “intermediate” microflora or BV microbiota, these 
methods do not differentiate between the 4 Lactobacillus species (L. crispatus, L. iners, L. jensenii, L. 
gasseri) that are commonly found in the general population.  Furthermore, the scoring is typically 
conducted only at the beginning of a trial, and thereby fails to account for the potentially rapid shifting 
nature of the microbiota.  Such imperfect categorization of vaginal microbiota may have precluded the 
field from better understanding the barrier properties of CVM to date. Since L. iners is commonly found 
in women who have had episodes of BV or intermediate microflora, it is very likely that risks are even 
higher, as the published analyses may have included a significant population of women with L. iners-
dominated (or even intermediate/BV) microflora in the “healthy” vaginal microbiota group that may not 
adequately protect against HIV or other STIs.  Thus, the actual risk factor for women with BV or L. iners 
may be markedly higher (e.g., >5 fold).  Correspondingly, women with L. crispatus-dominated 
microbiota may be much less likely to acquire HIV and other STIs.  If true, this would make reducing the 
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prevalence of BV and increasing the prevalence of L. crispatus one of the most effective protective 
strategies against HIV transmission. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Culture and purification of fluorescent HIV-1 
Replication defective HIV, internally labeled with mCherry-Gag was used in all the microscopy 
studies. Virus stocks were prepared by transfecting 293T cells with the plasmids pNL4-3.Luc.R-.E- (this 
reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pNL4-
3.Luc.R–.E– from Dr. Nathaniel Landau) along with the Gag-mcherry and YU2 gp160 Envelope encoding 
vectors provided by Dr. Suryaram Gummuluru (Department of Microbiology, Boston University School 
of Medicine, MA,USA) and Dr. Julie Nelson (University of North Carolina, Chapel Hill, NC, USA) 
respectively.  The 293T cells were obtained from Dr. Julie Nelson (University of North Carolina, Chapel 
Hill, NC, USA). 293T cells were maintained in Dulbecco’s modified Eagle’s medium (SIGMA, St. Louis, 
MO) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (DMEM-10). All cell 
cultures were maintained at 37°C in a humidified 5% CO2 atmosphere.  293T cells (2.0 × 106) were 
seeded in a 25cm2 flask (Thermo Scientific, Rochester, NY) and transfected with the expression plasmids 
using the X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics Corp, IN). The DNAs of 
pNL4-3.Luc.R-.E- along with Gag-mcherry and YU2 gp160 Envelope were mixed in a 4:1:1 ratio 
respectively, and added to 500 µl of serum free DMEM and 9 µl X-tremeGENE HP DNA Transfection 
Reagent. The mixture was incubated at room temperature for 30 min and then applied to the culture of 
293T cells. After 3 to 5 hr incubation at 37°C, transfected cells were washed extensively with DMEM and 
incubated for additional 24-48 hrs with 2 ml of DMEM-10, at 37°C in 5% CO2. The supernatants from 
virus particle producing cultures were then collected and were clarified by centrifugation for 10 min at 
1500 rpm, filtered through low protein binding 0.45 µm syringe filter (Millipore, Bedford, MA) and 
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partially purified through 25% wt/vol sucrose in Hepes-NaCl buffer by centrifugation at 36000 × g at 4°C 
for 2.5 hr. The pellet was resuspended overnight at 4°C in 10% sucrose in Hepes-NaCl buffer and used 
immediately or stored at -80°C.  
2.3.2 Cervicovaginal mucus (CVM) collection and characterization 
CVM collection was performed as published previously [8, 9].  Briefly, undiluted CVM 
secretions, averaging 0.3 g per sample, were obtained from women of reproductive age, ranging from 20 
to 33 years old (24.7 ± 0.74 years, mean ± SEM), by using a self-sampling menstrual collection device 
following protocols approved by the Institutional Review Board of the University of North Carolina – 
Chapel Hill.  Informed consent of participants was obtained after the nature and possible consequences of 
the study were explained.  The device was inserted into the vagina for at least 30 s, removed, and placed 
into a 50 mL centrifuge tube.  Samples were centrifuged at 230 x g for 2 min to collect secretions.  
Aliquots of CVM for lactic acid measurements (diluted 1:5 with 1x PBS and stored at –80°C) and slides 
for gram staining were prepared immediately, and the remainder of the sample was stored at 4°C until 
microscopy, which was typically performed within a few hours.  Samples were collected at random times 
throughout the menstrual cycle, and cycle phase was estimated based on the last menstrual period date 
normalized to a 29 day cycle.  No samples were ovulatory based on visual observation (none exhibited 
spinnbarkeit).  Samples that were non-uniform in color or consistency were discarded.  Donors stated they 
had not used vaginal products nor participated in unprotected intercourse within 3 days prior to donating.  
All samples had pH <4.5; none had bacterial vaginosis (BV) based on Gram staining and Nugent scoring, 
following scoring criteria described previously [41].  For lactic acid measurements, CVM aliquots were 
thawed and centrifuged for 2 min at 21,130 x g to obtain cell-free supernatant containing lactic acid.  
Lactic acid content was measured using a D-/L-lactic acid kit (R-Biopharm, Darmstadt, Germany) 
according to manufacturer protocol, but adapted to a 96-well format. 
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2.3.3 Multiple particle tracking of HIV-1 and synthetic beads in CVM 
Control beads consisted of red or green fluorescent 200 nm carboxyl-modified polystyrene 
particles (Molecular Probes, Eugene, OR), either uncoated (PS; muco-adhesive) or covalently conjugated 
with low molecular weight (2 kDa), amine-functionalized polyethylene glycol (PEG; Rapp Polymere, 
Tuebingen, Germany) to produce coated particles (PS-PEG; muco-inert), as previously described [10].  
Fluorescent virions or control beads (approximately 108–109 particles/mL) were added at 5% v/v to 20 µL 
of CVM placed in a custom-made glass chamber, and incubated for 1 hr at 37°C prior to microscopy.  
The translational motions of the particles were recorded using an EMCCD camera (Evolve 512; 
Photometrics, Tucson, AZ) mounted on an inverted epifluorescence microscope (AxioObserver D1; 
Zeiss, Thornwood, NY), equipped with an Alpha Plan-Apo 100x/1.46 NA objective, environmental 
(temperature and CO2) control chamber and an LED light source (Lumencor Light Engine 
DAPI/GFP/543/623/690).  Videos (512 x 512, 16-bit image depth) were captured with MetaMorph 
imaging software (Molecular Devices, Sunnyvale, CA) at a temporal resolution of 66.7 ms and spatial 
resolution of 10 nm (nominal pixel resolution 0.156 µm/pixel) for 20 s.  Particle trajectories were 
analyzed using a custom developed MatLab routine based on IDL; image contrast was adjusted to 
improve particle visibility, but the same contrast level was applied throughout the entire video and did not 
bias toward any particle population.  Trapped particles were defined as those with effective diffusivity 
(Deff) < 0.01 µm2/s at a time scale (τ) of 1 s (i.e., particles move less than their diameter within 1 s).  In a 
subset of experiments, we confirmed that particles defined as trapped over the course of 20 s based on this 
criterion remain confined to the same locations over more than 15 min.  At least five independent 
experiments in CVM from different donors, with n ≥100 particles per experiment, were performed for 
each condition.   
2.3.4 Microbiome Analysis using 16S rRNA gene sequencing 
 The 16S rRNA gene-based characterization of the vaginal microbial population was 
performed using procedures developed, validated, and published by The Institute for Genome Sciences 
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(IGS) at the University of Maryland [14, 34].  The extraction protocol provided between 5 and 10 µg of 
high quality whole genomic DNA from vaginal swabs measured using the Quant-iT PicoGreen dsDNA 
assay kit (Invitrogen). Barcoded universal primers 319F and 806R were used for PCR amplification of the 
V3-V4 hypervariable regions of 16S rRNA genes similar to Srinivasan et al. [35] but adapted for 
sequencing on the Illumina MiSeq platform. Amplicons were purified, quantified, and pooled.  Sequence 
data were generated on the Illumina MiSeq instrument using a protocol that generates 250 bp paired-end 
reads. Sequence read quality were assessed using a bioinformatics pipeline that is in accordance with 
standard operating procedures of the NIH Human Microbiome Project [14, 36, 37]. Briefly, raw sequence 
reads were filtered to meet the following criteria: 1) minimum and maximum read length of 150 bp and 
250 bp; 2) no ambiguous base calls; 3) the read were discarded or trimmed if the average quality value is 
less than q20 within a sliding window of 25 bp; 5) sixty percent match to a previous 16S rRNA gene 
sequences; 6) chimera-free using UCHIME software [38]. These criteria had been implemented in a 
custom-designed bioinformatics pipeline deployed at IGS. Paired-reads were first assembled; if one of the 
paired reads was not available, the mate read was not used. These quality control steps were critical to 
guarantee the quality and integrity of the analyses. Sequence reads with the same barcode were binned by 
sample. Species-level taxonomic assignments of each sequence read were performed using the placer 
algorithm or a combination of the Ribosomal Database Project (RDP) Bayesian classifier and SpeciateIT 
as previously described [14, 39].  For each sample, vectors of phylotype proportions were clustered into 
CSTs described by Gajer et al. [40]. Estimate of stability and change were evaluated using the rate of 
change of the Jensen-Shannon distance as previously described [40] as well as assignment of each 
longitudinal pattern of CSTs to community classes [40]. Community class is an estimate of community 
dynamics that takes into account the community composition over time. Five community classes had 
previously been identified in 32 non-pregnant healthy women [40].  
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2.3.5 Statistical analysis 
A two-tailed Student’s t-test was used for all comparisons.  Differences were deemed significant 
at an alpha level of 0.05.  All values are reported as mean ± SEM unless otherwise indicated. 
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Figure 2.1. Fraction of particles or virions classified as mobile in cervicovaginal mucus specimens from 
different donors (N=8). PS-COOH (carboxylated polystyrene nanoparticles, d ~ 200 nm) which were 
previously shown to be relatively sticky to mucus in pH 7 CVM; PS-PEG (PEG-coated polystyrene 
nanoparticles, d ~ 200 nm) which were previously shown to be relatively muco-inert in pH 7 CVM; 
mCherry-GAG tagged HIV virus-like particles pseudotyped with YU2 envelope in CVM at native (i.e. 
unaltered) pH; mCherry-GAG tagged HIV virus-like particles pseudotyped with YU2 envelope in CVM 
adjusted to neutral pH with <3% dilution with 3N NaOH.  Symbols in blue represents CVM specimens 
where HIV exhibited substantial mobile fractions at native pH.  
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Figure 2.2. The ensemble averaged diffusivity of particles or virions classified as mobile in 
cervicovaginal mucus specimens from different donors (N=8). PS-COOH (carboxylated polystyrene 
nanoparticles, d ~ 200 nm) which were previously shown to be relatively sticky in pH 7 CVM; PS-PEG 
(PEG-coated polystyrene nanoparticles, d ~ 200 nm) which were previously shown to be relatively muco-
inert in pH 7 CVM; mCherry-GAG tagged HIV virus-like particles pseudotyped with YU2 envelope in 
CVM at native (i.e. unaltered) pH; mCherry-GAG tagged HIV virus-like particles pseudotyped with YU2 
envelope in CVM adjusted to neutral pH with <3% dilution with 3N NaOH.  Symbols in blue represents 
CVM specimens where HIV exhibited substantial mobile fractions at native pH (see Figure 2.1C).  
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Figure 2.3. Fraction of mobile virions for mCherry-GAG tagged HIV virus-like particles pseudotyped 
with YU2 envelope in CVM at native (i.e. unaltered) pH, correlated to native CVM pH, Nugent Score, 
endogenous D-lactic acid (D-LA) levels in CVM, endogenous L-LA levels in CVM, and total LA levels 
in CVM (N=8).  Symbols in blue represents CVM specimens where HIV exhibited substantial mobile 
fractions at native pH (see Figure 2.1C). 
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Figure 2.4. Ensemble averaged diffusivities for mCherry-GAG tagged HIV virus-like particles 
pseudotyped with YU2 envelope in CVM at native (i.e. unaltered) pH, correlated to native CVM pH, 
Nugent Score, endogenous D-lactic acid (D-LA) levels in CVM, endogenous L-LA levels in CVM, and 
total LA levels in CVM (N=8).  Symbols in blue represents CVM specimens where HIV exhibited 
substantial mobile fractions at native pH (see Figure 2.1C). 
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Figure 2.5: CVM that traps HIV appear to be L. crispatus- dominant, whereas CVM that fails to 
trap HIV are either L. iners- dominant, or include substantial G. vaginalis.  (A) Representative of the 
dominant bacterial spp. present in vaginal secretions from three samples that were able to immobilize 
HIV virions in native pH conditions.  (B) Representative of the dominant bacterial spp. present in vaginal 
secretions from three samples that did not provide a barrier against HIV virions in native pH conditions. 
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Table 2.1: Characterization of CVM samples: pH, Cycle day, Menstrual cycle phase, D-LA/L-
LA/total LA in g/L, and Nugent Score. 
1Cycle day calculated as the number of day from the first of the last menstrual period normalized by the 
cycle length to a 29 day cycle. 2N/A = hormonal contraceptive. 3N/A = donor with abnormal cycle, could 
not calculate cycle day.  4N/A = no menstrual cycle info for donor.  5Cycle phase estimated based on 
normalized cycle day; no samples were ovulatory based on absence of spinnbarkeit by visual inspection.  
6Values are expressed as mean ± SD.  7A Nugent score of 0-3 corresponds to “normal” (lactobacilli-
dominated) microflora, 4-6 to “intermediate”, and 7-10 to “bacterial vaginosis” (BV) – a condition 
associated with greater risk of STI acquisition.  Assessment of Nugent scores was independently 
confirmed by the Clinical Microbiology and Immunology Lab at UNC – Chapel Hill.  8Waiting on results. 
Donor 
ID/Date pH 
Cycle 
day1 
Menstrual 
Cycle5 D-LA
6 L-LA Total LA  Nugent Score7 
F5 120508 4.07 n/a2 luteal 3.24 ± 0.99 4.99 ± 0.53 8.23 ± 0.47  1 
F20 120508 4.04 26 luteal 2.99 ± 0.092 3.81 ± 0.96 6.80 ± 0.86 1 
F11 120509 3.95 n/a2 n/a 3.28 ± 0.17 3.51 ± 0.74 6.79 ± 0.57 1 
F28 120509 4.30 n/a2 luteal 3.58 ± 0.92 2.72 ± 0.38 6.30 ± 0.55 2 
F14 120514 4.52 n/a2 n/a 2.09 ± 0.63 3.17 ± 0.86 5.27 ± 0.23 1 
F3 120515 4.32 13 follicular 1.84 ± 1.1 4.13 ± 0.98 5.97 ± 0.08 6 
F23 120517 4.05 27 luteal 3.56 ± 0.29 2.50 ± 0.41 6.07 ± 0.70 0 
F25 120517 4.38 n/a2 follicular 1.74 ± 0.17 1.76 ± 0.29 3.50 ± 0.45 3 
F2 120521 4.30 n/a2 luteal 7.17 ± 1.7 4.37 ± 0.24 11.54 ± 1.9 0 
F11 120522 4.20 22 luteal 1.65 ± 0.37 6.01 ± 0.52 7.67 ± 0.89 4 
F12 120523 3.72 n/a2 follicular 9.74 ± 0.27 8.16 ± 0.14  17.90± 0.41 1 
F29 120524 3.64 n/a2 follicular 5.67± 1.5 3.75 ± 0.075 9.42 ± 1.6 0 
F34 120524 3.91 25 luteal 0.75 ± 0.035 6.62 ± 0.52 7.37 ± 0.49 4 
F4 120525 4.10 n/a2 follicular 0.73 ± 0.25 10.29 ± 0.19 11.02 ± 0.43 3 
F19 121119 5.22 n/a2 n/a 2.29 ± 0.20 2.76 ± 0.20 5.05 ± 0.40 1 
F37 121119 3.97 n/a2 follicular 0.16 ± 0.044 9.15 ± 1.69 9.32 ± 1.7 3 
F26 121120 3.99 n/a2 luteal 4.14 ± 2.8 2.99 ± 0.56 7.13 ± 3.3 0 
F27 121120 4.00 n/a2 luteal 1.55 ± 0.047 5.74 ± 0.13  7.29 ± 0.09 0 
F33 121217 3.98 n/a3 n/a 2.88 ± 0.31 1.98 ± 0.30 4.86 ± 0.01 0 
F36 121218 4.06 n/a2 luteal 0.21 ± 0.021 8.63 ± 2.69 8.83 ± 2.7 4 
F15 121218 3.88 n/a2 luteal 4.30 ± 0.86 2.23 ± 0.065 6.54 ± 0.80 0 
F44 131021 3.90 n/a4 n/a 6.80 ± 0.43 2.65 ± 0.56    9.45 ± 0.99 n/a8 
F13 140114 4.20 20 luteal 2.86 ± 0.53 4.99 ± 1.6  7.85 ± 1.1 n/a 
F21 140116 4.00 26 luteal 4.15 ± 2.4 6.80 ± 0.86 10.9 ± 3.3 n/a 
F23 140116 4.09 16 luteal 1.45 ± 0.050 3.57 ± 0.35 5.0 ± 0.30 n/a 
F25 140117 4.28 n/a2 follicular 1.33 ± 0.18 5.48 ± 1.5 6.82 ± 1.7 n/a 
F35 140117 4.84 29 luteal 1.78 ± 0.89 4.94 ± 0.28 6.28 ± 0.61 n/a 
25	  
	  
Donor	  ID/Date	   Age	  	  	  	  	  	   Race	   Birth	  Control	  
F5	  120508	   26	   African	  American	   Nuvaring	  
F20	  120508	   24	   African	  American	   no	  
F11	  120509	   25	   Caucasian	   Loestrin	  
F28	  120509	   20	   Caucasian	   Loestrin	  24	  
F14	  120514	   32	   Caucasian	   Orthocept	  
F3	  120515	   28	   Caucasian	   no	  
F23	  120517	   19	   Other	   no	  
F25	  120517	   27	   Caucasian	   Lutera	  
F2	  120521	   28	   Caucasian	   Loestrin	  24	  Fe	  
F11	  120522	   25	   Caucasian	   no	  
F12	  120523	   26	   Caucasian	   Loestrin	  
F29	  120524	   21	   Caucasian	   azurette	  
F34	  120524	   26	   African	  American	   no	  
F4	  120525	   27	   Caucasian	   Microgestin	  
F19	  121119	   26	   Caucasian	   IUD	  
F37	  121119	   20	   Asian	   Yes1	  
F26	  121120	   22	   Caucasian	   Trisprintec	  
F27	  121120	   24	   Caucasian	   Avaine	  
F33	  121217	   22	   Caucasian	   no	  
F36	  121218	   23	   Asian	   Reclipsen	  
F15	  121218	   30	   Caucasian	   Junel	  Fe	  
F44	  131021	   20	   Caucasian	   no	  
F13	  140114	   33	   Caucasian	   no	  
F21	  140116	   21	   African	  American	   no	  
F23	  140116	   21	   Other	   no	  
F25	  140117	   29	   Caucasian	   Lutera	  
F35	  140117	   21	   Asian	   no	  
 
Table 2.2: Characterization of CVM samples: Age, Race, and birth control. 
1Donor did not specify the brand of birth control, just expressed the fact that the birth control used were 
oral contraceptives. 
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